SARS‑CoV‑2 questions on Step exams rarely want you to regurgitate a timeline—they want you to recognize patterns: an enveloped +ssRNA virus with spike‑mediated entry, a distinctive immune response (including cytokine storm), and a disease spectrum tied to age/comorbidities and vaccination status. Here’s a quick-hit, shareable set of tables + mnemonics + one‑liners to lock in the highest yield facts.
10‑second identity (what you must know cold)
SARS‑CoV‑2 is a Coronavirus: enveloped, positive‑sense single‑stranded RNA virus that replicates in the cytoplasm and uses ACE2 for cell entry.
One-liner: “Enveloped +ssRNA coronavirus that uses ACE2 via Spike and can cause anything from anosmia to ARDS via diffuse alveolar damage.”
Visual mnemonic: “CROWN with a KEY”
Picture a crown (corona) with a key:
- CROWN = Coronavirus envelope studs (spikes)
- KEY = Spike (S) protein is the key that unlocks ACE2
- Door hinges = TMPRSS2 helps prime Spike for fusion/entry (high yield association)
One-liner: “Spike is the key, ACE2 is the lock, TMPRSS2 helps turn the key.”
Comparison Table #1: Virology basics (SARS‑CoV‑2 vs classic high‑yield viruses)
| Feature | SARS‑CoV‑2 (Coronavirus) | Influenza A (Orthomyxovirus) | RSV (Paramyxovirus) | Adenovirus |
|---|---|---|---|---|
| Genome | +ssRNA | –ssRNA, segmented | –ssRNA | dsDNA |
| Envelope | Enveloped | Enveloped | Enveloped | Non‑enveloped |
| Replication site | Cytoplasm | Nucleus (exception for RNA viruses) | Cytoplasm | Nucleus |
| Key surface protein | Spike (S) | HA/NA | F protein | Fiber protein |
| Entry receptor | ACE2 (plus cofactors like TMPRSS2) | Sialic acid | Heparan sulfate (varies) | CAR receptor |
| Notable mechanism | Spike-mediated fusion/endocytosis | Antigenic drift/shift | Syncytia via F | Lytic infection; conjunctivitis |
| Typical “testable” clinical clue | Anosmia/ageusia, hypoxemia, ground-glass opacities | Abrupt fever + myalgias | Bronchiolitis in infants | Pharyngoconjunctival fever |
Comparison Table #2: Structural + genomics “buzzwords” that show up in stems
| High-yield fact | What it means | How it appears on USMLE |
|---|---|---|
| +ssRNA genome | Can function as mRNA | Rapid replication; cytoplasmic lifecycle |
| Enveloped virus | Lipid membrane | Inactivated by detergents/soap; less stable on surfaces vs non-enveloped (but still transmissible) |
| Spike (S) protein | Binds receptor + mediates entry | Target of neutralizing antibodies; vaccines largely aim here |
| ACE2 receptor | Highly expressed in respiratory epithelium (also GI, endothelium) | Respiratory + GI symptoms; vascular complications |
| Cytokine-driven injury | Dysregulated host response | ARDS, shock, elevated inflammatory markers |
| Hypercoagulability | Endothelial activation/inflammation | DVT/PE risk; microthrombi; severe hypoxemia |
One-liners you can drop into any question
- Transmission: “Primarily respiratory—droplets/aerosols in close contact settings.”
- Incubation: “Often a few days; asymptomatic transmission is a classic clue.”
- Core pulmonary pathology in severe disease: Diffuse alveolar damage → ARDS (hyaline membranes).
- Classic imaging buzzword: Ground-glass opacities (nonspecific but commonly tested).
- Anosmia/ageusia: early clue pointing you toward SARS‑CoV‑2 over “generic viral URI.”
- Multisystem complications: “Not just pneumonia—think thrombosis + inflammation + end-organ dysfunction.”
Pathogenesis flow (Step-friendly)
- Entry: Spike binds ACE2 (primed by proteases like TMPRSS2)
- Replication: Cytoplasmic replication → viral production
- Local disease: Upper → lower respiratory tract involvement
- Severe disease (host response):
- Diffuse alveolar damage → ARDS
- Endothelial inflammation → hypercoagulability (microthrombi, PE)
- Systemic inflammation → shock, organ injury
Clinical spectrum: quick comparison table
| Category | Typical features | High-yield exam twist |
|---|---|---|
| Mild/moderate | Fever, cough, sore throat, fatigue, anosmia/ageusia, GI symptoms | Many are mild; don’t overcall pneumonia |
| Severe pulmonary | Dyspnea, hypoxemia, diffuse infiltrates | ARDS physiology (refractory hypoxemia) |
| Thrombotic | DVT/PE, stroke, microvascular thrombosis | Clues: sudden worsening hypoxemia, pleuritic CP, unilateral leg swelling |
| Pediatric inflammatory | Fever + systemic inflammation after infection | Think MIS‑C style presentation (post-infectious hyperinflammation) |
Diagnostics: what the test writers expect
| Test | Detects | When it’s useful | High-yield pitfall |
|---|---|---|---|
| NAAT/PCR | Viral RNA | Acute infection | Most sensitive early; sampling matters |
| Antigen test | Viral proteins | Quick, best with higher viral load | More false negatives vs NAAT |
| Serology | Antibodies | Prior infection/vaccine response (context dependent) | Not for diagnosing early acute infection |
Treatment & prevention (Step-relevant framing)
Most tested concept: Supportive care + oxygen escalation for hypoxemia; antivirals/immunomodulation depend on severity and timing.
- Supportive: oxygen, fluids as needed, manage complications
- Severe inflammatory lung disease: immunomodulation may be used in hospitalized patients with significant oxygen needs (concept: treat the host inflammatory phase)
- Prevention: vaccination reduces severe disease risk; enveloped virus → soap/hand hygiene is effective
(On exams, you’re more likely to be tested on “who gets severe disease and why” and “what complication is happening” than memorizing specific brand-name regimens.)
Micro “rapid-fire” mnemonics (print-and-share style)
1) “Corona = Cytoplasm”
One-liner: “Coronavirus is an RNA virus that replicates in the cytoplasm (unlike influenza).”
2) “Spike → Smell loss”
One-liner: “Spike-mediated ACE2 entry + upper airway involvement: think anosmia/ageusia.”
3) “COVID CLOTTING”
One-liner: “Inflammation + endothelial injury → hypercoagulability (DVT/PE/microthrombi).”
Ultra-high-yield “Step stem” patterns to recognize
- Enveloped RNA virus + ground-glass opacities + anosmia → SARS‑CoV‑2
- Worsening hypoxemia out of proportion + signs of thrombosis → consider PE/microthrombi
- Severe respiratory failure with diffuse infiltrates → ARDS from diffuse alveolar damage
- Aerosol spread in indoor/crowded settings + asymptomatic transmission → classic public health angle
Quick recap table (the “sticky note”)
| Must-know | Answer |
|---|---|
| Virus family | Coronavirus |
| Genome | +ssRNA |
| Envelope | Yes |
| Replication | Cytoplasm |
| Entry | Spike → ACE2 (TMPRSS2 helps) |
| Key complications | ARDS, thrombosis, systemic inflammation |
| Classic clues | Anosmia/ageusia, ground-glass opacities |
Frequently Asked Questions
How do you tell SARS-CoV-2 from influenza, RSV, or adenovirus on a virology question?
SARS-CoV-2 is distinguished by being an enveloped positive-sense single-stranded RNA coronavirus that replicates in the cytoplasm and uses ACE2 for entry via its Spike protein. Common exam clues include anosmia or ageusia, hypoxemia, and ground-glass opacities. In contrast, influenza A is a segmented negative-sense RNA virus, RSV is linked to syncytia and bronchiolitis in infants, and adenovirus is a non-enveloped dsDNA virus.
Why does SARS-CoV-2 cause ARDS and severe hypoxemia?
SARS-CoV-2 causes ARDS and severe hypoxemia through diffuse alveolar damage driven by the host inflammatory response. After Spike-mediated entry through ACE2 and viral replication in the cytoplasm, infection can spread from the upper to lower respiratory tract. In severe disease, cytokine-driven injury produces diffuse alveolar damage with hyaline membranes, leading to ARDS physiology and refractory hypoxemia.
Why is hypercoagulability such an important complication in SARS-CoV-2 infection?
Hypercoagulability is important because SARS-CoV-2 can trigger endothelial inflammation and activation, which promotes thrombosis. This can lead to DVT, PE, microthrombi, and severe hypoxemia, making the illness more than just a viral pneumonia. On exams, clues such as sudden worsening hypoxemia, pleuritic chest pain, or unilateral leg swelling should raise concern for a thrombotic complication.
What test is best for acute SARS-CoV-2 infection?
NAAT or PCR is the most useful test for acute SARS-CoV-2 infection because it detects viral RNA and is most sensitive early in illness. Antigen tests detect viral proteins and are quicker, but they have more false negatives than NAAT, especially when viral load is lower. Serology detects antibodies and is more useful for prior infection or vaccine response, not early acute diagnosis.
Why is soap effective against SARS-CoV-2?
Soap is effective against SARS-CoV-2 because it is an enveloped virus with a lipid membrane. Enveloped viruses are inactivated by detergents and soap, which disrupt that membrane. This is a classic structural clue tested alongside the idea that enveloped viruses are generally less stable on surfaces than non-enveloped viruses, even though they still spread efficiently through respiratory transmission.